1月8日，在上海舉行的光華科技公益論壇上，國家傳染病醫學中心主任、復旦大學附屬華山醫院感染科主任張文宏表示，一些自媒體說奧密克戎引發的是“大號流感”，這是缺乏科學依據的，他研究奧密克戎感染者的醫學影像後認為，這種變異株“會咬人”。一個國家和地區需要強大的免疫屏障和醫療資源，才能抵禦奧密克戎的威脅。
"Omicron is not a 'big flu', and it can bite, especially for people without strong immunity," Zhang Wenhong, leader of the COVID-19 treatment expert team of Shanghai and head of Fudan University Huashan Hospital's infectious disease department, said at a science forum in Shanghai last week.
He said that successfully fending off the threat of Omicron requires building robust herd immunity and preparing sufficient medical resources.
圖源：新華社
張文宏認為，西方國家之所以在“硬闖”這波疫情，其底氣主要來自疫苗，其效果有待進一步評估。目前，美國的新冠疫苗接種率接近70%，三針疫苗接種率是22%，所以大多數健康的年輕人有望平安“闖”過這波疫情，但免疫力低下的人群呢？前景不容樂觀。英國近期每天新增確診人數超過20萬，但病死率沒有明顯上升。究其原因，是英國的新冠疫苗接種率達到80%，三針疫苗接種率超過50%，且尚未出現嚴重的醫療資源擠兌情況。
Some Western countries, despite a significant increase in daily new infections, have managed to lower their COVID-19 death rates because of high vaccination coverage, according to Zhang.
除了不斷提高疫苗兩針及以上的接種率，一個國家或地區還要確保醫療資源的充分供給，這樣才能對免疫力低下的感染者進行充分救治。“如果醫療資源不夠，奧密克戎是會‘咬人’的。”張文宏說，“我國各地都要確保醫療資源的充分和平等。”
"We should further expand initial immunization and the rolling out of booster shots," he said at the forum. "Meanwhile, it is important to ensure adequate provision of healthcare resources in different regions so that immunocompromised people infected with the novel coronavirus can be treated effectively."
根據國家衛健委11日通報，全國新冠疫苗接種劑次超29億。
According to the National Health Commission, China had administered more than 2.9 billion doses of COVID-19 vaccines as of Tuesday.
張伯禮：奧密克戎的後遺症還不清楚
中國工程院院士張伯禮稱，奧密克戎的特點是傳播快、隱匿性強、穿透力強，所以我們對它非常警覺。
Zhang Boli, an academician with the Chinese Academy of Engineering and a top traditional Chinese medicine expert, said the Omicron variant appears to be more elusive and to spread more easily.
他認為，說奧密克戎是大號流感是不恰當的，雖然它傳染性強、症狀比較輕，但是它有沒有後遺症，現在還不清楚，根據國外的資料分析，新冠肺炎的後遺症還是比較多的，遠遠高於流感，所以“乾脆放開”“群體免疫”的做法，我覺得是不負責任的。“動態清零”我們已經堅持了兩年，是成功的。
The fast-spreading variant should not be treated like influenza, because it can pose severe risks to unvaccinated people and its long-term effects on recovered patients still remain unclear, Zhang said.
"Although most local patients only have mild symptoms, it is not appropriate to treat it as a 'big common cold'," he said. "Data from overseas have shown that a large number of Omicron patients have exhibited lingering effects after recovery, and the proportion is higher than that for influenza."
As a result, it would be irresponsible to loosen virus control restrictions, Zhang said, adding that China's "zero-COVID-19" policy should be capable of tackling the new strain's local spread.
"Mass vaccination should be ramped up further, as vaccines' effect in preventing serious cases and deaths remains strong," he said.
世衛組織：奧密克戎並不“溫和”
此外，世界衛生組織已於6日發出警告稱，儘管新冠病毒變異株奧密克戎引發重症的風險低於先前流行的其他變異株，但它仍在全球多國造成人員死亡，因而不宜將這一毒株的特性描述為“溫和”。
Maria Van Kerkhove, the WHO's technical lead on COVID-19, said recently on social media, "While some reports show a reduced risk of hospitalization of Omicron compared to Delta, there are still far too many people infected, in hospital sick & dying from Omicron (& Delta)".
世衛組織新冠疫情技術主管範·科霍夫近日在社交媒體上稱，“雖然一些報告顯示，奧密克戎導致的住院率略低於德爾塔，但仍有太多人感染，生病住院，或死於奧密克戎（和德爾塔）。”
In another post on social media, she said: "Omicron is not mild. Omicron is not flu or the common cold. SARS-CoV-2 is not endemic yet. Now is not the time to give up," she said.
在另一則貼文中，她說：“奧密克戎並不溫和，它不是流感或普通感冒。新冠病毒還不是地區性流行病。現在還不是懈怠的時候。”
記者：王小予
編輯：左卓
來源：中國日報 上觀新聞 新華社
China Daily精讀計劃來了！
每天20分鐘，
帶你學英語，看世界！
